Valuation : Curis, Inc.

Market Cap 3.11M 2.68M 2.52M 2.3M 4.32M 296M 4.35M 29.83M 11.61M 150M 11.69M 11.44M 498M P/E 2026 *
-0.06x
P/E 2027 * -0.21x
Enterprise Value 3.11M 2.68M 2.52M 2.3M 4.32M 296M 4.35M 29.83M 11.61M 150M 11.69M 11.44M 498M EV / Sales 2026 *
-
EV / Sales 2027 * 0.34x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Curis, Inc.

1 week-5.70%
Current month-70.32%
1 month-70.32%
3 months-85.77%
6 months-92.48%
Current year-92.45%
1 week 1.4
Extreme 1.4
1.64
1 month 1.4
Extreme 1.4
5.5
Current year 1.4
Extreme 1.4
24.2
1 year 1.4
Extreme 1.4
39
3 years 1.4
Extreme 1.4
349.8
5 years 1.4
Extreme 1.4
3,554
10 years 1.4
Extreme 1.4
7,440
Manager TitleAgeSince
Chief Executive Officer 59 24/09/2018
Director of Finance/CFO 54 05/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 01/11/2003
Chairman 84 16/05/2017
Director/Board Member 71 03/06/2010
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Free

Chief Executive Officer

110,090 0.2824%
07/07/26 Free

Director

6,800 0.0174%
07/07/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.70%-95.46%-99.33% 3.11M
-0.21%-2.42%+0.46%+17.32% 49.81B
-1.11%-2.84%+420.04%+505.15% 44.06B
-0.21%+0.37%+36.88%+17.32% 42.99B
-1.95%-3.33%+8.29%+73.25% 40.88B
-0.94%-1.77%+18.34%+46.84% 33.11B
-1.11%-4.20%+25.49%+119.78% 16.58B
+6.10%+4.40% - - 17.27B
+0.17%-1.94%+11.79%+28.25% 14.63B
-1.12%-3.46%+76.50%+39.37% 13.76B
Average -0.06%-1.80%+55.81%+83.11% 27.31B
Weighted average by Cap. -0.42%-1.50%+88.77%+122.55%

Financials

2026 *2027 *
Net sales - 9.25M 7.96M 7.48M 6.83M 12.82M 880M 12.92M 88.61M 34.48M 446M 34.73M 33.98M 1.48B
Net income -52.02M -44.79M -42.05M -38.39M -72.12M -4.95B -72.63M -498M -194M -2.51B -195M -191M -8.31B -45.23M -38.94M -36.57M -33.38M -62.71M -4.3B -63.16M -433M -169M -2.18B -170M -166M -7.23B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
31/08/26 $1.490 -.--% 35,842
28/08/26 $1.490 -0.67% 119,833
27/08/26 $1.500 -2.60% 288,289
26/08/26 $1.540 -3.14% 105,410
25/08/26 $1.590 +0.63% 142,438
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.490USD
Average target price
42.67USD
Spread / Average Target
+2,763.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock